Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05852938
Registration number
NCT05852938
Ethics application status
Date submitted
2/05/2023
Date registered
10/05/2023
Date last updated
20/05/2024
Titles & IDs
Public title
A Study of BION-1301 in Adults With IgA Nephropathy
Query!
Scientific title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
Query!
Secondary ID [1]
0
0
CHK02-02
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
IgA Nephropathy
0
0
Query!
Immunoglobulin A Nephropathy
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BION-1301
Treatment: Drugs - Placebo
Experimental: BION-1301 - 600mg subcutaneous administration every 2 weeks for 104 weeks
Placebo Comparator: Placebo - subcutaneous administration every 2 weeks for 104 weeks
Treatment: Drugs: BION-1301
BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.
Treatment: Drugs: Placebo
Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in proteinuria
Query!
Assessment method [1]
0
0
The change in urine protein: creatinine ratio (UPCR) from baseline to Week 40.
Query!
Timepoint [1]
0
0
40 weeks or approximately 9 months
Query!
Secondary outcome [1]
0
0
Change in eGFR
Query!
Assessment method [1]
0
0
The change in eGFR from baseline to Week 104.
Query!
Timepoint [1]
0
0
104 weeks or approximately 2 years
Query!
Eligibility
Key inclusion criteria
- Male and female subjects aged = 18 years at the time of signing the informed consent
form (ICF) prior to initiation of any study specific activities/procedures.
- Biopsy-proven IgAN diagnosed within the past 10 years prior to Screening, that, in the
opinion of the Investigator, is not due to secondary causes. A pseudonymized copy of
the report must be available for review by the Sponsor or designee prior to
randomization. If biopsy report within 10 years is not available, re-biopsy may be
permitted upon discussion with the Medical Monitor.
- eGFR = 30 mL/min/1.73m^2 at Screening based on the 2021 CKD-EPI equation.
- Total urine protein = 1.0 g/day and UPCR = 0.7 g/g (700 mg/g), as measured from an
adequate 24-hour urine collection at Screening by a central laboratory.
- Stable on a maximally tolerated dose of ACEi/ARB for at least 12 weeks prior to
Screening unless intolerant to ACEi/ARB. May also be on a stable and well tolerated
dose of SGLT2i and/or ERAs/MRAs for at least 12 weeks prior to Screening for the
treatment of IgAN. Subjects are expected to stay on the ACEi/ARB, SGLT2i and/or the
ERAs/MRAs for the duration of the study.
- Body mass index (BMI) between 18 and 40 kg/m^2.
- Screening weight of 45 to 150 kg.
- Men and women of childbearing potential (WOCBP; per Clinical Trials Facilitation and
Coordination Group [CTFG] 2020) must agree to follow protocol-specified contraception
guidance from Screening through approximately 5 half-lives (24 weeks) after the final
dose of study drug. Use of hormonal contraceptive agents must have been initiated > 1
month prior to first dose of study drug.
- Provide written informed consent and be willing to comply with study visits and
procedures.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Secondary forms of IgAN as determined by the Investigator, in the setting of systemic
disorders, infections, autoimmune disorders or neoplasias.
- Diagnosis of IgA Vasculitis.
- Current or history of nephrotic syndrome.
- Average blood pressure > 150/90 mm Hg (systolic/diastolic) from 3 readings obtained at
the initial Screening visit. If blood pressure is too high, the 3 readings may be
repeated once within the Screening period if clinically appropriate as per the
Investigator.
- Clinical suspicion of IgAN with rapidly progressive glomerulonephritis (RPGN) based on
KDIGO guidelines
- Chronic Kidney Disease, either clinically suspected or based on biopsy, resulting from
any condition or another glomerulopathy/podocytopathy other than IgAN.
- History of Type 1 Diabetes.
- Subjects with Type 2 diabetes are excluded if any of the following are present:
- Screening HbA1c (glycated hemoglobin) of > 8%.
- Evidence of diabetic changes on kidney biopsy, performed for any reason.
- History of diabetic microvascular disease (retinopathy, neuropathy, nephropathy)
and/or macrovascular disease (atherosclerotic heart disease, peripheral vascular
disease, cerebrovascular disease).
- Unstable anti-diabetic regimen:
- Prior exposure to any antibody directed against APRIL.
- History of a previous severe allergic reaction with generalized urticaria, angioedema,
or anaphylaxis, including a history of allergy or hypersensitivity to any component of
BION-1301, or history of severe hypersensitivity reaction to any monoclonal antibody.
- Received an investigational new drug within 28 days or 5 half-lives, whichever is
longer, prior to Screening.
- Received systemic corticosteroid therapy including budesonide (Tarpeyo/Kinpeygo) for >
14 days within 12 weeks prior to Screening.
- Use of systemic immunosuppressant medications.
- Any confirmed or suspected immunosuppressive or immune-deficient state, including but
not limited to common variable immunodeficiency (CVID), HIV infection or asplenia,
history of bone marrow or organ transplantation with exception of corneal transplants.
- Current severe infection requiring antimicrobials or history of recurrent, severe,
infections as determined by the Investigator.
- Positive serology test for hepatitis A virus IgM antibodies (anti-HAV IgM), hepatitis
B surface antigen (HBsAg), detectable hepatitis B virus (HBV) DNA, hepatitis C virus
(HCV) antibodies (subjects who completed treatment and are persistently antibody be
allowed), or antibodies to HIV-1 and/or HIV-2 at Screening.
- Received a live vaccination within 12 weeks prior to Screening or plan to have a live
vaccination within 6 months after the last dose of study drug.
- History of malignancy unless cancer free for at least 5 years or non-melanoma skin
cancer that was completely resected. A subject with curatively treated cervical
carcinoma in situ is eligible for the study. Subjects with low-risk prostate cancer
(i.e., Gleason score < 7 and prostate specific antigen < 10 ng/mL) are allowed.
- Pregnancy or breastfeeding or intent to become pregnant or to donate sperm during the
study period and until 24 weeks after last dose.
- History or evidence of any other clinically significant disorder, condition, disease,
or laboratory finding that, in the Investigator's assessment, would place the subject
at unacceptable risk, limit compliance with study requirements, or confound
interpretation of study results.
- IgG levels < 6 g/L at Screening.
- Participation in another interventional trial with an investigational agent/device is
prohibited during the course of this study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/07/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
8/05/2028
Query!
Actual
Query!
Sample size
Target
292
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Renal Research - Gosford
Query!
Recruitment hospital [2]
0
0
St George Hospital - Kogarah
Query!
Recruitment hospital [3]
0
0
Nepean Hospital - Penrith
Query!
Recruitment hospital [4]
0
0
Cairns Hospital - Cairns North
Query!
Recruitment hospital [5]
0
0
Box Hill Hospital-5 Arnold St - Box Hill
Query!
Recruitment hospital [6]
0
0
Sunshine Hospital - Australia - St Albans
Query!
Recruitment postcode(s) [1]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
2750 - Penrith
Query!
Recruitment postcode(s) [4]
0
0
4870 - Cairns North
Query!
Recruitment postcode(s) [5]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [6]
0
0
3021 - St Albans
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Pennsylvania
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
South Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Tennessee
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Virginia
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Ciudad Autónoma De BuenosAires
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Santa Fe
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Ciudad Autónoma de Buenos Aires
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Ontario
Query!
Country [18]
0
0
Korea, Republic of
Query!
State/province [18]
0
0
Seoul Teugbyeolsi
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Chinook Therapeutics, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05852938
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-888-669-6682
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05852938
Download to PDF